Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. - Laporan Laba Rugi (TTM)

Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.
CN ˙ SZSE
CN¥ 34.68 ↑0.68 (2.00%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 446 509 633 784 821 784 691 586 584 610 619 631 623 593 604 592 586 605 611
Change (%) 13.96 24.36 23.88 4.75 -4.54 -11.80 -15.25 -0.27 4.35 1.52 1.91 -1.22 -4.78 1.79 -1.95 -0.94 3.24 0.99
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 241 263 303 356 374 367 349 329 334 350 354 361 368 359 371 366 364 376 380
Change (%) 9.13 15.41 17.35 5.16 -1.84 -4.99 -5.66 1.58 4.80 1.20 1.76 1.92 -2.31 3.27 -1.43 -0.51 3.28 1.06
% of Revenue 53.90 51.61 47.90 45.37 45.54 46.83 50.45 56.16 57.20 57.45 57.27 57.18 59.01 60.54 61.42 61.75 62.01 62.04 62.08
Gross Operating Profit 206 246 330 428 447 417 342 257 250 259 264 270 255 234 233 226 223 230 232
Change (%) 19.61 33.91 29.89 4.42 -6.80 -17.80 -25.02 -2.64 3.75 1.95 2.11 -5.43 -8.34 -0.48 -2.79 -1.63 3.18 0.87
% of Revenue 46.10 48.39 52.10 54.63 54.46 53.17 49.55 43.84 42.80 42.55 42.73 42.82 40.99 39.46 38.58 38.25 37.99 37.96 37.92
SG&A 77 88 108 122 144 142 135 132 141 149 156 161 144 142 135 128 146 144 146
Change (%) 15.31 22.22 13.14 17.56 -1.58 -4.52 -1.94 6.33 5.46 4.87 3.56 -10.70 -1.33 -5.09 -4.96 13.83 -1.19 1.49
% of Revenue 17.19 17.39 17.09 15.61 17.52 18.06 19.55 22.62 24.12 24.37 25.18 25.58 23.13 23.97 22.35 21.66 24.89 23.82 23.94
R&D 24 25 31 37 42 44 41 39 37 36 37 36 36 39 38 40 40 38 38
Change (%) 6.48 24.46 17.59 14.11 4.86 -8.18 -3.96 -5.72 -1.58 1.66 -1.88 0.46 6.75 -0.39 3.32 -0.52 -3.84 -0.50
% of Revenue 5.30 4.95 4.96 4.71 5.13 5.63 5.86 6.64 6.28 5.92 5.93 5.71 5.81 6.51 6.37 6.72 6.74 6.28 6.19
OpEx 347 383 450 523 569 560 531 507 518 535 545 545 551 548 553 555 553 562 571
Change (%) 10.28 17.46 16.37 8.67 -1.48 -5.19 -4.61 2.23 3.30 1.88 0.01 1.14 -0.57 0.91 0.26 -0.24 1.62 1.57
% of Revenue 77.76 75.25 71.08 66.76 69.26 71.48 76.83 86.48 88.65 87.75 88.07 86.43 88.49 92.41 91.61 93.68 94.34 92.86 93.39
Operating Income 99 126 183 260 252 224 160 79 66 75 74 86 72 45 51 37 33 43 40
Change (%) 26.82 45.34 42.36 -3.12 -11.42 -28.37 -50.55 -16.25 12.61 -1.10 15.91 -16.25 -37.18 12.49 -26.13 -11.34 30.36 -6.55
% of Revenue 22.24 24.75 28.92 33.24 30.74 28.52 23.17 13.52 11.35 12.25 11.93 13.57 11.51 7.59 8.39 6.32 5.66 7.14 6.61
Interest Expense -7 -6 -6 -6 -5 -3 -2 -1 -1 -1 -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) -4.96 -1.48 -9.77 -15.92 -28.79 -38.88 -43.73 -49.31 18.64 -45.17 12.62 0.04 -45.89 13.62 -39.14 51.66 -0.49 55.17
% of Revenue -1.52 -1.27 -1.01 -0.73 -0.59 -0.44 -0.30 -0.20 -0.10 -0.12 -0.06 -0.07 -0.07 -0.04 -0.04 -0.03 -0.04 -0.04 -0.06
Net Income 81 103 151 214 216 206 164 108 94 96 98 106 118 95 95 81 50 57 56
Change (%) 27.10 46.10 41.46 1.07 -4.61 -20.27 -34.22 -13.25 2.23 1.87 8.98 10.83 -19.14 -0.51 -14.77 -38.69 15.53 -1.65
% of Revenue 18.23 20.33 23.89 27.27 26.32 26.30 23.77 18.45 16.05 15.72 15.78 16.87 18.93 16.08 15.71 13.66 8.45 9.46 9.21

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista